Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAFU granules
- Development stage
- Phase 3
- Lead developer
- Beijing Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
MAFU granules is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, for the treatment of idiopathic membranous nephropathy (IMN). The name "MAFU" is derived from its core herbal components, Ma Huang (Ephedra) and Fu Zi (Aconite). The regimen follows the "Wenyang Jiebiao" principle, which translates to warming the yang and relieving the exterior, a strategy used in TCM to address edema and kidney dysfunction. It is currently being evaluated in a randomized Phase 2–3 clinical trial in China, where its efficacy and safety are compared against the immunosuppressant cyclosporine in adult patients with moderate to high-risk IMN.
- Other names
- Wenyang Jiebiao RegimenMAFU Granules
Beyond the preview
Go deeper on MAFU granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAFU granules.